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Prognostic factors in multiple myeloma
STEFANIE BRINK, D. BRADSHAW, W. J. C. J. ROSENSTRAUCH,
ALETTA M. VAN DER MERWE
Summary
All patients with multiple myeloma seen over a 9-
year period at Tygerberg Hospital were studied retro-
spectively. Presentation data of 144 patients, as well
as individual laboratory results were included in the
survival analysis. Cox's proportional hazard model (a
non-parametric multivariate regression method) was
used to predict survival and divide patients into
prognostic groups. The relationship between pairs of
variables at the time of diagnosis was investigated.
The survival of groups of patients was compared
using the generalized Wilcoxon and Savage tests.
The association of the following factors with prog-
nosis were again substantiated: haemoglobin; serum
creatinine, urea and albumin; percentage of plasma
cells in the bone marrow aspirate and trephine biopsy
specimen; and the number of lytic lesions on skeletal
radiography. The following factors were not substan-
tiated: serum uric acid, light-chain proteinuria, age at
presentation of the disease and IgG rather than the
IgA class. In addition, a higher serum monoclonal
peak size at presentation of the disease, and a more
rapid fall in the abnormal serum monocional peak
within the first 40 days after commencing treatment
were associated with a significantly longer survival.
S Air Med J 1986; 69: 35-38.
Certain clinical parameters have been assumed to be important
for prognosis in patients with multiple myeloma, and have
been related to the tumour-load. Such factors include pre-
treatment levels of haemoglobin,I,2 serum urea, serum crea-
tinine/,4 serum uric acid/,4 serum calcium,I,4 serum M-pro-
tein,I,5 serum albumin,2 the presence and type of light-chain
proteinuria (kappa or lambda),5 proteinuria other than light
chains,5 the percentage of plasma cells in the bone marrow
aspirate,4 the number of lytic bone lesions seen on radiography, I
age at presentation of the illness2 and the general clinical
status.6 Salmon and Smith7 used direct8 and indirect9 methods
for the calculation of the tumour cell mass in multiple myeloma
in 1970, and they described three clinical stages. Their work
was based on experimental studies by Hobbs. 5 Woodruff er al. 1
used this staging system in a clinical evaluation and they
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demonstrated highly significant differences in the survival of
patients with low, intermediate and high tumour cell mass.
These results were also corroborated in other clinical series. J.g
The Acute Leukemia Group BIO in 1975 and Matzner er aP in
1977 reported that patients with IgA myeloma had a signifi-
cantly shorter survival than those with IgG, but this could not
be substantiated in other series. 11 Patients on therapy with a
fast fall in tumour size survived for a shorter period than those
who responded more slowly.'2 Pennec er al.,13 however, in a
large multicentric study, could not demonstrate any significant
differences in the survival of these three 'stages' of multiple
myeloma. According to them, only the haemoglobin level is
significant as a 'classic' criterion of survival. They recognized
that kidney failure, thrombocytopenia, fever, increased percen-
tage of plasma cells in the bone marrow and higher age were
significant factors associated with shorter survival. Bemstein
and Humes,14 however, pointed out that kidney failure with
multiple myeloma is reversible in 55% of patients. Treatment
of hypercalcaemia and/or chemotherapy for the illness is asso-
ciated with reversibility of kidney failure in 88% of cases and
thus improved survival. The association with survival has
already been identified for some of these prognostic factors,
but further research was indicated for many others.
In this study all patients seen with multiple myeloma at this
hospital were analysed for prognosis and response to therapy
over a period of 9 years. Data at presentation, serial laboratory
results and treatment group were analysed with non-parametric
multivariate statistical techniques to investigate their relation-
ship to patient survival.
Patients and methods
All the patients with multiple myeloma seen at Tygerberg Hospital
from I January 1975 to 31 December 1983 were included. Patients'
referral and hospital records before this time were too incomplete
for inclusion. In this study of 144 patients the date of the deaths
of 72% of the patients were known, 22% were alive on 31 December
1983 and only 6% had to be excluded for incomplete follow-up.
The diagnostic criteria followed at Tygerberg Hospital are those
recognized by the Eastern Cooperative Oncology Group of the
USA.15
For every patient in the study the following details were
recorded:
Data recorded at initial presentation
Race and sex, date of birth, age at presentation, number of lytic
lesions on skeletal radiography and the number of fractures, the
place of the monoclonal peak on protein electrophoresis, the
presence of light-chain proteinuria and the immunoglobulin class
were recorded. Bone marrow trephine biopsy was introduced as a
routine investigation only during the latter part of the 9-year
course of this study, so that the percentage of plasma cells were
evaluated in some of the earlier patients only on their bone
marrow aspirate. The aspirate report provided a convenient per-
centage figure in contrast with the trephine biopsy results which
frequently reported 'patchy infiltration'. In a few of the recent
patients, where the aspirate resulted in a 'dry tap', the percentage
of plasma cells was re-evaluated from the trephine biopsy
specimen.
TABLE I. MEAN, SO AND THE NUMBER OF OBSERVATIONS
FOR SOME OF THE PROGNOSTIC FACTORS AT
PRESENTATION
of multiple myeloma. In 13 patients no final decision about the
class was available from the records. In 7 patients no documentation
about the immunoglobulin class was available. On skeletal radio-
graphy of 138 patients, 40 demonstrated no lytic lesions, 10
patients had a solitary lytic lesion,S had 2 lesions, 17 had between
3 and 5 lesions and 66 had 6 or more lytic lesions. Table I shows
the means, standard deviations and the number of observations for
some of the data at presentation.
Relationship between factors
The non-parametric Spearman rank-order correlation method
was used and the correlations have been based on all available
information. The following statistically significant correlations
were found:
(I) Haemoglobin with percentage of plasma cells (P = 0,0009),
serum IgM (P = 0,0032), serum creatinine (P = 0,0001), serum
albumin (P = 0,001) and monoclonal peak size (P = 0,0085).
(il) Percentage of plasma cells with lytic lesions (P = 0,0092).
(iil) Serum IgM with lytic lesions (P = 0,014), serum protein (P
= 0,0008) and IgG (P = 0,0001).
(iv) Serum creatinine with serum calcium (P = 0,0054), serum
urea (P = 0,0001) and uric acid (P = 0,0001).
(v) Serum albumin with serum calcium (P = 0,0116), LD (P =
0,0061), AST (P = 0,0001) and serum AP (P = 0,0236).
(VI) Monoclonal peak size with serum creatinine (P = 0,0084),
serum protein (P = 0,0001) and serum albumin (P = 0,0001).
Significant correlations were found in 38 other pairs of prog-
nostic factors but have been omiued from this article to assist
clarity. The large number of highly significant correlations
increased the difficulty of the final interpretation of the statistics,
and necessitated the use of Cox's regression analysis.
The following differences were found between the race groups
based on the one-way ANOVA and Student's ( test: serum albumin
was significantly higher in whites than in blacks, and levels in
blacks were significantly higher than in coloureds (P = 0,0009).
The abnormal serum monoclonal peak was significantly higher in
coloureds than in blacks, and significantly higher in blacks than in
whites (P = 0,0033). Haemoglobin values were significantly higher
in blacks than in whites (P = 0,0272) but those of coloureds and
whites were not significantly different.
Haemoglobin values were significantly higher in males than in
females (P = 0,001), the percentage of plasma cells on the bone
marrow was higher in the females than in the males (P = 0,003)
and the extent of the drop of the abnormal serum monoclonal
peak values after presentation was significantly higher for females
than for males (P = 0,0362). .
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Serial data
The following serial results were recorded at subsequent visits:
haemoglobin, total white cell count and platelet count (Coulter
model S plus, Coulter model S or Coulter model F). The following
serial tests were performed on an SMAC 20-channel system:
serum calcium (mmolll),'6· I7 lactate dehydrogenase (LD~,18 alkaline
phosphatase (AP),'. alanine transaminase (ALT), 1,1 aspartate
transaminase (AST)2° and gamma-glutamyl transaminase (GGT)
(V/I at 37°C),21 total serum bilirubin (TSB) (JlmoVI),22 serum
urea (mmoVI),23 serum uric acid (mmoVI),24 serum creatinine
(JlmoVI) and total serum protein (g/I). For the serum albumin
level and the monoclonal peak height (g/I) a Beckman microsone
cellulose acetate electrophoresis system was used.
For light-chain proteinuria (qualitative) a fresh urine specimen
preserved with sodium oxide was used. If the protein electro-
phoresis on concentrated urine showed globulin, the presence of
free kappa or lambda chains was investigated by immuno-electro-
phoresis.
Therapeutic programmes
Various therapeutic programmes have been used at Tygerberg
Hospital since 1975. The first was standard oral therapy using
melphalan and prednisone (treatment I). The second had cyclo-
phosphamide added (treatment 2). Treatment 3 also contained
vincristine and treatment 4 consisted of melphalan/prednisone/
carmustine (BCNV)/cyclophosphamide and vincristine. The
therapy was changed depending on drug toxicity or patient non-
response. The longest or most important regimen was selected for
the purpose of the analysis. Treatment I was given to 66 patients,
37 received treatment 2, IS received treatment 3, IS received
treatment 4 and II patients were not treated for multiple myeloma.
Statistical analysis
An exploratory investigation of the serial data was undertaken by
plouing all the observations during the course of the disease to
evaluate whether any of the variables showed consistent trends.
The relationship between pairs of variables at the time of diagnosis
was investigated using the Spearman rank correlation coefficient
in the case of continuous variables and the Student (-test or one-
way analysis of variance in the case of a continuous variable being
compared with a categorized one. The generalized Wilcoxon test
and the Savage test were used to compare the survival of groups of
patients (for example males v. females). These are non-parametric
tests which can accommodate censored observations, and which
differ by the weighting given to the survival over time. Cox's
proportional hazard regression model was used with the presenta-
tion data as covariates for prediction of the survival times to
investigate which factors could be used to predict a patient's
prognosis.
The proportional hazard model is given by
h(t;~) = Ho(t) exp (1f1)
in terms of «h(t;!;)) the hazard rate ('instantaneous death rate' at
time t) for a person with covariate ~ (t represents the time in
days), Ji is a vector with the unknown regression coefficients and
ho(t) is the hazard rate for a person with~=.Q.
Estimates of the regression coefficient were made with an
iterative technique similar to the maximum likelihood ratio test.
To evaluate the effect of all the variables (prognostic factors) on
the hazard rate, the variables were introduced stepwise into the
regression, and with each step the statistical significance was
evaluated. The covariates were all tested at a significance level of
5%. This analysis was undertaken on the IBM 4341 computer
using the BMDP2L program.
0/0 plasma cells
Haemoglobin
Serum urea
Serum creatinine
Serum protein
Serum albumin
Serum monoclonal peak size
Serum IgG
Serum IgM
Serum IgA
Mean
46,03
10,55
11,60
231,06
91,58
31,84
34,61
40,09
0,58
5,38
SO
27,04
2,77
11,77
336,70
22,48
7,08
23,83
34,80
0,52
13,54
Results
Fifty-nine white males, 36 white females, 23 coloured males, 13
coloured females, 10 black males and 3 black females were included
in the study. Ninety-two patients were IgG, 23 were IgA, 8 had
light-chain proteinuria and I patient had the non-secretory class
Serial information
Very few consistent trends were observed in the serial data.
Representative samples of patients were selected with stratified
random methods and all the serial variables of these patients were
ploued. Only the haemoglobin, the monoclonal peak size and the
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Fig. 1. Survival curves for white males and females.
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LD appeared to follow general trends during the course of the
disease. The serial data relating to all the subjects were then
plotted for these variables. The haemoglobin increased slowly
after diagnosis, and dropped slightly before the death of the
patient; however, this tendency was not completely consistent.
The peak appeared to drop rapidly within the first month and was
then followed by a gradual increase. No consistent trend was
observed in the LD when all the subjects were considered.
Relationship between factors and survival
The total group of 144 patients had a median survival time of
390 days, i.e. 50% of the patients died within 13 months of
diagnosis. Several factors were found to be significantly associated
with survival time.
On the basis of the Savage test, white males experienced a
better survival than white females (P = 0,0303). The survival
times of the two groups are illustrated in Fig. I. It can be seen
that although the initial survival is poorer in' females, both groups
have long-term survivors. Fig. 2 shows that the survival of patients
on treatment 1 was worse than that of patients on other treatments
(P = 0,029). Cox's regression analysis was used to consider the
relationship between continuous variables and survival allowing
for adjustment for the treatment group (1 or others), the race,
gtOUp and sex by including them as factors in the model. Longer
survival time was associated with increased haemoglobin (P =
0,011), serum albumin (P = 0,015) and the extent of the mono-
clonal peak drop during the first 40 days (P = 0,04). Shorter
survival was associated with an increased number of lytic lesions
(P = 0,007), percentage of plasma cells (P = 0,003), total white
cell count (P = 0,005), serum creatinine (P = 0,001), serum urea
(P = 0,002), serum AP (P = 0,003) and serum IgM (P = 0,002).
When the 54 patients with a positive serum monoclonal peak
size were divided into two equal groups on the basis of being
above or below the median drop within the first 40 days, it was
found that those patients with a larger fall in monoclonal peak size
were associated with a longer survival than those with a smaller
drop (P = 0,0432). Fig. 3 illustrates the survival of the two groups
of patients.
When only those variables significantly associated with survival
on their own were included in the stepwis,: procedure, in combina-
tion with TSB and the monoclonal peak size (two additional
variables which were selected in the stepwise procedure when all
the variables had been included), the analyses were conducted on
92 cases. These results are given in Table II. Treatment I, higher
plasma cells in the bone marrow aspirate, serum IgM and serum
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creatinine were associated with shorter survival (the proportionality
factor eP' is greater than 1), while higher serum albumin and
monoclonal peak size were associated with longer survival (the
proportionality factor eP' is less than I).
Discussion
The presence of certain factors at the time the disease manifests
has already been associated with prognosis; this was substan-
tiated in our study. These factors are: higher haemoglobin
and/or serum albumin, which indicate longer survival; and
higher number of lytic lesions on radiography, percentage of
plasma cells in the bone marrow aspirate, total white cell
count, and serum urea, creatinine and AP, which indicate a
shorter survival time.
In our series: (I) a higher serum monoclonal peak size at
presentation of the disease; and (il) a larger fall in the serum
monoclonal peak size than the median drop within the first 40
days after presentation were both associated with longer sur-
vival. This is contrary to the findings of Alexanian el al. 12 and
Salmon and Smith7 based on the experimental work by Hobbs. 5
It should be noted that peak size and peak drop are significantly
associated (P = 0,001), and it is also logical to expect that a
higher peak at presentation can lead to a faster fall. A low peak
is also associated with treatment 1 and this could be a con-
founding factor. It is, however, interesting that when the total
number of 144 patients was divided into three equal groups on
the basis of the size of the serum monoclonal peak at the time
of presentation of the disease, the median survival for the
patients with a low (or absent) peak was 435 days, the middle
peak was 510 days and the high peak was 875 days. Although
the groups did not differ significantly, a trend was apparent.
Our study demonstrated a significant difference in the
survival rate of the earlier patients, who were treated with only
melphalan and prednisone, in contrast with the rate in later
patients on various other combinations.
White males survived significantly longer than white females.
Females probably presented at a later stage of the disease, or
had possibly been misdiagnosed in the earlier stages. It is
significant that: (I) the percentage of plasma cells was higher in
females than in males (therefore shorter survival); (il) the peak
drop was higher for females (therefore longer survival); and
(iil) the haemoglobin values were lower for females (therefore
shorter survival).
All these contradictory facts complicate or mask the role of
gender in survival. When the role of gender was evaluated in
the multivariate statistical methodology it was not selected as a
significant prognostic variable.
Our study did not substantiate the following factors as being
of prognostic importance in the survival rate - serum uric
acid, presence of light-chain proteinuria, age at presentation of
the disease, and the IgG rather than the IgA class.
No ethnic differences were found in the survival rates but
few black patients were included and they did not survive for
long. This could be because the diagnosis was made at a later
stage of the disease.
The stepwise Cox's proportional hazard model fined to the
data indicated that for any patient a value above the average
for percentage of plasma cells, serum IgM and/or serum
creatinine meant an increased hazard or a poorer prognosis.
Values above average levels for serum albumin and/or mono-
clonal peak size indicate a decreased hazard or a bener prog-
nosIs.
This formula has been calculated on retrospective data for
patients seen at Tygerberg Hospital, and it is not necessarily
applicable to patients seen at other hospitals investigated at
other laboratories. Serum IgM was selected as an important
prognostic variable and it was significantly associated with
serum IgG and protein, haemoglobin and the number of lytic
lesions. At the moment there is no satisfactory explanation for
the selection of serum IgM.
In addition to the data being collected retrospectively from
hospital records, the stage of the disease at presentation has
been assumed to be consistent for all the patients. The conse-
quent inherent degree of unreliability in these data could well
mask any true correlation. It is therefore not surprising to find
discrepancies with other studies and even within this study.
Despite the inadequacies of the design of these types of
studies, it is felt that they are useful in indicating possible
associations which can be used in formulating hypotheses
which can be further investigated.
This study once again demonstrates the use of retrospective
statistical analysis of routine hospital data. Presentation data of
144 patients with multiple myeloma, as well as the individual
serial laboratory results of the follow-up years were included
in the survival analysis. The prediction model that emerged
can now be used with advantage in ensuring comparability of
patients in future prospective studies. For example, the predic-
tive survival can help in meaningful formation of comparable
groups for stratified randomizations in future chemotherapeutic
trials.
This study was supported by the South African Medical
Research Council.
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